Lexpert Special Editions

www.lexpert.ca 31 offering of 10,747,900 units at a price of $1.07 per unit for gross proceeds of approximately $11.5 million, which includes the exercise in full of the under- writers' over-allotment option. Each unit consists of one common share of Havn and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at an exercise price of $1.34 for a period of 36 months. Cassels Brock & Blackwell LLP acted for Havn with a deal team that included Deepak Gill, Sean Baraich and Aamir Chherawala (securities). Blake, Cassels & Graydon LLP acted for the underwriter, Eight Capital, with a deal team that included Linda Tu, Lauren Leah and Connor Anear. CDL RAPID SCREENING CONSORTIUM PILOT PROGRAM CLOSING DATE: JANUARY 2021 e CDL Rapid Screening Consortium is a private led non-profit organization focusing on the development of a cost-effective system to reopen the economy during the COVID-19 pandemic without widely avail- able vaccines or treatments. e consortium is focused on establishing a rapid screening system and operational implementation strategy for COVID-19 to benefit the public in Canada and the rest of the world. e system will serve as an added layer of protec- tion in conjunction with social distancing, mask wearing and pre-screening employees. e innovative new screening program is led by the Creative Destruction Lab and includes as members 11 diverse companies including Air Canada, Rogers, Scotiabank, Maple Leaf Sports & Entertainment, Magna, CPP Investment Board, Genpact, MDA Corporation, Nutrien, Shoppers Drug Mart and Suncor. As the first of its kind, the consortium aims to launch an antigen rapid testing program to combat the COVID-19 pandemic by protecting its employees and by publishing a playbook for businesses throughout Canada to reopen safely. Aer collaborating for several months, the consortium has created an operating manual on how to run rapid antigen tests in work settings and has begun piloting testing in their workplaces. e group intends to share the system for free with their competi- tors and plans to share its tests results with government health authorities, providing an informal study of the spread of COVID-19 among asymptomatic people. Osler Hoskin & Harcourt LLP supported the launch of CDL Rapid Screening Consortium's pilot program with a team consisting of Chad Bayne (emer- ging and high growth companies), Andrew MacDougall, Kojo Hayward (corporate), Joanna Fine and Komil Joshi (privacy and data management). AURINIA PHARMACEUTICALS INC. DEVELOPMENT AND COMMERCIAL- IZATION OF LUPKYNIS COMPLETION DATE: DEC. 17, 2020 LUPKYNIS, an oral therapy for the treat- ment of lupus nephritis (LN), has completed its clinical trials for the treatment of LN and was approved on Jan. 22, 2021 by the U.S. Food and Drug Administration, in combination with a background immuno- suppressive therapy regimen to treat adult patients with active LN. LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events and death. Aurinia Pharmaceuticals Inc. has a collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of LUPKYNIS in Europe and Japan. is is valued at US$50 million upfront payment in addition to up to US$50 million in regulatory and reimbursement milestone payments. e agreement includes royalties ranging from 10 to 20 per cent on net sales payable to Aurinia, along with additional sales-based milestones. Farris LLP acted as licensing counsel to Aurinia Pharmaceuticals Inc. MINDBEACON HOLDINGS INC. IPO CLOSING DATE: DECEMBER 2020 On Dec. 17, 2020, MindBeacon Holdings Inc. priced its initial public offering consisting of a treasury offering of 8,125,000 common shares at a price of $8 per common share for aggregate gross proceeds of $65 million. e common shares began trading on the TSX on Dec. 18, 2020 under the symbol "MBCN". e offering closed on Dec. 23, 2020. e offering was led by TD Securities Inc. and Credit Suisse Securities (Canada), Inc. as joint bookrunners, Canaccord Genuity Corp. as co-lead underwriter and Bloom Burton Securities Inc., Beacon Securities Limited and Echelon Wealth Partners Inc. as underwriters. MindBeacon, the company's online plat- form, launched in 2017 as one of the first commercially available, digitally native platforms offering therapist-assisted inter- net-based Cognitive Behavioural erapy in Canada. Osler Hoskin & Harcourt LLP advised MindBeacon, with a team consisting of François Paradis, Shahir Guindi, Jason Comerford, Marisa Corona, Natasha Gould, Jie Chai, Kelsey Weiner (corporate), Manon ivierge, Jennifer Lee, Kaleigh Hawkins- Schulz (tax) and Susan Newell (health). Davies Ward Phillips & Vineberg LLP advised the underwriters, with a team including Steven Cutler, Simon Kaplan, Shane Freedman, Julie Colden, Jeffrey Nadler and Gregg Benson.

• Cover